Table 2.
Treatment Related Adverse Events
| Adverse Event | Grade | 500mg | 2000mg |
|---|---|---|---|
| Lymph node pain | 3 | 1 | 0 |
| Lymphatics-other | 3 | 1 | 0 |
| ↓ Neutrophil count | 3 | 0 | 1 |
| Anorexia | 2 | 2 | 0 |
| Arthritis | 2 | 0 | 1 |
| Bone pain | 2 | 1 | 0 |
| Constipation | 2 | 1 | 1 |
| Dehydration | 2 | 1 | 0 |
| Fatigue | 2 | 4 | 3 |
| Glucose tolerance impaired | 2 | 1 | 0 |
| Headache | 2 | 0 | 1 |
| ↓ Hemoglobin | 2 | 0 | 2 |
| Hyperglycemia | 2 | 0 | 1 |
| Hypoalbuminemia | 2 | 0 | 1 |
| Hypotension | 2 | 1 | 0 |
| Leukopenia | 2 | 1 | 0 |
| Musculoskeletal disorder | 2 | 0 | 1 |
| Nausea | 2 | 1 | 0 |
| ↓ Neutrophil count | 2 | 1 | 1 |
| Pain in extremity | 2 | 1 | 0 |
| Tooth infection | 2 | 0 | 1 |
Includes all grade 2 and above toxicities considered possible, likely, or probably related to cilengitide.